wire - news in brief




Page not found (Error 404)





Category



Results 151 - 200 of 373.


Pharmacology - Health - 30.09.2019
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev

Health - Pharmacology - 30.09.2019
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec

Pharmacology - Health - 30.09.2019
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint ,   IRIDIUM is largest study in Phase III PLATINUM clinical development p

Pharmacology - Health - 30.09.2019
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu

Pharmacology - Health - 29.09.2019

Pharmacology - Health - 28.09.2019
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea

Pharmacology - Health - 27.09.2019
Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil

Pharmacology - Health - 27.09.2019
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So

Environment - Life Sciences - 27.09.2019
Nine new professors appointed
Energy systems, cryptography and computer-aided simulation; interactions between people, animals and landscape, investigation of biosystems from the human brain to the nanometer scale: the incoming professors work in a wide range of cutting-edge research fields.

Life Sciences - Event - 26.09.2019
Congratulations to our prize winners
Congratulations to our prize winners
A highlight at the FMI Annual Meeting 2019, which has taken place last week in the Swiss Alps (Grindelwald), was the Award Ceremony: the winners of the Ed Fischer Prize for best thesis, the Max Burge

Astronomy / Space Science - Materials Science - 25.09.2019
SwissCube still going strong 10 years on
The tiny Swiss satellite, launched in September 2009, is still working. The fact that it has lasted so long is a testament to the skills of the students who built it.

Physics - Chemistry - 24.09.2019
A chip to measure vacuums
A chip to measure vacuums
Vacuums are a vital part of the processes - such as freeze-drying - used to make and preserve countless everyday items and must be measured with precision. An EPFL spin-off, Hexisense, is bringing to market a gallium nitride-based chip that can measure the quantity of certain gas molecules cheaply and with unrivalled precision.

Innovation - Computer Science / Telecom - 24.09.2019
The EU supports secure quantum communication
The EU supports secure quantum communication
Four Swiss organisations, including UNIGE, receive funding from the European Union (EU) through OPENQKD, a secure quantum communication infrastructure.

Innovation - Business / Economics - 23.09.2019

Innovation - 23.09.2019
History of technology: accolades to USI researcher Maria Rikitianskaia
The International Committee for the History of Technology (ICOHTEC) honoured Maria Rikitianskaia for her doctoral work which was unanimously voted as the best book on the history of technology, published in 2019 by young researchers. The researcher of USI Institute of Media and Journalism won the Turriano ICOHTEC Prize , dedicated to the best book on the history of technology written by a young researcher.

Pharmacology - Health - 23.09.2019
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici

Computer Science / Telecom - Innovation - 20.09.2019
EPFL develops solution for detecting deepfakes
EPFL develops solution for detecting deepfakes
Deepfakes - or fake videos produced to look real through the use of artificial intelligence - pose a growing challenge.

Health - Pharmacology - 20.09.2019
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti

Life Sciences - Health - 19.09.2019
How to construct a protein factory
How to construct a protein factory
The complexity of molecular structures in the cell is amazing. Having achieved great success in elucidating these structures in recent years, biologists are now taking on the next challenge: to find out more about how they are constructed. A joint research project between two groups from the University of Bern and ETH Zurich now provides insight into a very unusual construction process in the unicellular parasite Trypanosoma brucei.

Pharmacology - Health - 19.09.2019
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1

Agronomy / Food Science - Event - 19.09.2019
Solutions for the future of nutritional research
Every day, we choose the food we eat and influence our health, whether consciously or not. This link between diet and health is a core concern of nutritional scientists, who met in Bern from 7 to 12 September 2019 for the 16th annual conference of the NuGO nutrigenomics association.

Materials Science - Event - 18.09.2019

Pharmacology - Health - 18.09.2019
FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Full results from the NOBILITY study will be presented at a medical meeting later this year Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis.

Health - Computer Science / Telecom - 17.09.2019
Prestigious grant to use Artificial Intelligence for improved glucose control
Prestigious grant to use Artificial Intelligence for improved glucose control
The ARTORG Center for Biomedical Engineering Research of the University of Bern is the recipient of a grant from JDRF, the leading global funder for type 1 diabetes research.

Pharmacology - Health - 17.09.2019
Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).

Innovation - Business / Economics - 13.09.2019

Pharmacology - Health - 13.09.2019
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos

Computer Science / Telecom - 13.09.2019

Pharmacology - Health - 13.09.2019
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ

Pharmacology - Health - 13.09.2019
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc

Administration - Career - 13.09.2019
Gabriele Bavota earns an ERC Starting Grant to develop an artificial assistant for software developers
Gabriele Bavota, Assistant Professor at the USI Software Institute (SI), is among the recipients of the latest ERC Starting Grants, the research funds awarded by the European Research Council on a highly competitive basis to the most promising young researchers active in Europe.

Pharmacology - Health - 12.09.2019
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of rela